With a focus on resolving various cardiovascular and cerebrovascular diseases, we have built a multi-level product portfolio. Compound Danshen Dripping Pills is our flagship product among an array of related products such as Yangxueqingnao (granules/pills), Qishenyiqi Dripping Pills, and injections such as Recombinant Human Prourokinase, Yiqi Fumai (freeze-dried), and Salvia Miltiorrhiza Polyphenolic Acid. The portfolio comprises products that are part of a comprehensive therapy for treating cardiovascular and cerebrovascular diseases. We have made significant efforts in the research and development of new Traditional Chinese Medicine (TCM) products and to improve the product life-cycle management. Our current products are focused on hyperlipidemia, platelet aggregation, heart failure, stroke as well as post-stroke recovery. We are also striving to fill the current void in the availability of stem-cell products for the treatment of cardiovascular and cerebrovascular diseases and build a comprehensive product portfolio suited for the prevention, treatment and recovery of such diseases. We are also working to provide a comprehensive solution to patients suffering from different stages of cardiovascular and cerebrovascular diseases.

We adopt a patient-centric approach. Our star product, Diqing (Temozolomide Capsules) has opened new possibilities in the treatment of glioma. Our time-proven flutamide and Xihuang Wan have helped to reduce costs for patients with prostate cancer and breast cancer. We are developing drugs and devices meant for colon cancer, pancreatic cancer, liver cancer, and multiple myeloma, to aid in early detection, prevention, diagnosis, and treatment of tumors.

Our star products, Shuilinjia and Jinghua Weikang, are designed for liver protection and treatment of stomach diseases. Xiaokeqing and Difumi (minodronic acid tablets) have great potential in treating diabetes and osteoporosis. We are stepping up R&D of innovative drugs and re-development of major products focusing on fatty liver, drug-induced liver diseases, H. pylori infection, diabetes, ulcerative colitis, and other diseases. These initiatives will expand our product portfolio and serve patients with chronic diseases in all stages of diseases.

We are committed to the cause of brain health in China , and our R&D focuses on various neurological diseases. Our star products in this area include Yangxue Qingnao (granules/pills), Wenfei (Dexzopiclone Tablets), Shaoma Zhijing Keli, and XingnaoJing (intravenous injection), which integrate oral and injectable TCMs and Western medicine.

Our products are used to treat chronic cerebral insufficiency, migraine, tension-type headache, hypertensive headache, and other common neurological diseases. Some products are used in the treatment and prognosis of life-threatening diseases such as stroke and cerebral infarction. In addition, we are strengthening R&D efforts to focus on sleep disorders, transient tic disorder, and other related diseases. Our products, Wenfei and Shaoma Zhijing granules, have filled the existing void in the market for such products. Soon, we will step up R&D of drugs and devices to focus on more segments such as vascular cognitive impairment, Alzheimer's disease, and other related diseases to eventually offer a full range of products and services for early detection, prevention, diagnosis, and treatment of neurological diseases.